Premium
Dexrazoxane protects the heart from acute doxorubicin‐induced QT prolongation: a key role for I Ks
Author(s) -
Ducroq J,
Moha ou Maati H,
Guilbot S,
Dilly S,
Laemmel E,
PonsHimbert C,
Faivre JF,
Bois P,
Stücker O,
Le Grand M
Publication year - 2010
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2009.00371.x
Subject(s) - dexrazoxane , doxorubicin , qt interval , herg , anthracycline , pharmacology , medicine , prolongation , epirubicin , potassium channel , anesthesia , chemotherapy , cancer , cyclophosphamide , breast cancer
Doxorubicin, an anthracycline widely used in the treatment of a broad range of tumours, causes acute QT prolongation. Dexrazoxane has been shown to prevent the QT prolongation induced by another anthracycline, epirubicin, but has not yet been reported to prevent that induced by doxorubicin. Thus, the present study was designed to test whether the acute QT effects induced by doxorubicin could be blocked by dexrazoxane and to explore the mechanism. Results were compared with those obtained with a reference human ether-a-go-go (hERG) channel blocker, moxifloxacin.